<DOC>
	<DOCNO>NCT01697514</DOCNO>
	<brief_summary>The purpose study find recommended dose level LY2940680 safely give child medulloblastoma rhabdomyosarcoma return n't respond initial treatment . The study also explore change cancer marker level . Finally , study help document antitumor activity .</brief_summary>
	<brief_title>A Study LY2940680 Pediatric Medulloblastoma Rhabdomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>For Part A : Have diagnosis recurrent refractory rhabdomyosarcoma medulloblastoma histologic verification malignancy original diagnosis relapse . For Part B : Have diagnosis recurrent refractory medulloblastoma histologic verification malignancy original diagnosis relapse . Current disease state must one know curative therapy therapy proven prolong survival acceptable quality life . Karnofsky score must least 50 % participant &gt; 16 year age , Lansky score must least 50 % participant 16 year age less . Participants unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Have fully recover acute toxic effect prior anticancer chemotherapy . Participants solid tumor must receive myelosuppressive chemotherapy within 3 week enrollment study ( 6 week , previously treat nitrosourea ) . Hematopoietic growth factor : At least 14 day last dose longacting growth factor ( eg , Neulasta® ) 7 day shortacting growth factor . Biologic ( antineoplastic agent ) : At least 7 day last dose biologic agent . Immunotherapy : At least 6 week since completion type immunotherapy ( eg , tumor vaccine ) . Monoclonal antibody : At least 3 halflives antibody last dose monoclonal antibody . Radiation therapy ( XRT ) : ≥8 week local irradiation primary tumor ; ≥2 week prior study entry focal irradiation symptomatic metastatic site ; ≥3 month craniospinal XRT , ≥24 week ≥50 % radiation pelvis ; minimum 6 week must elapse substantial bone marrow radiation receive . Stem cell transplant : allow recover acute toxicity adequate bone marrow reserve demonstrate . At least 8 week must elapse since autologous stem cell transplantation ≥3 month allogenic transplantation . Participants must immunosuppressive therapy evidence active graftversushost disease . Have adequate organ function , include : Bone marrow : Peripheral absolute neutrophil count ( ANC ) ≥500/cubic millimeter ( mm^3 ) platelet count ≥100,000/mm^3 ( transfusion independent , define receive platelet transfusion within 7day period prior enrollment ) . Hepatic : Bilirubin ( sum conjugate + unconjugated ) ≤1.5 × upper limit normal ( ULN ) age . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.0 time ULN age . Serum albumin ≥2 grams/deciliter ( g/dL ) . Renal : Creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥70 milliliters/minute/1.73 square meter ( mL/min/1.73 m^2 ) , serum creatinine base age/gender per Schwartz formula estimate GFR utilize child length stature data publish Centers Disease Control Prevention ( CDC ) . Neurologic : Participants seizure disorder may enrol receive nonenzymeinducing anticonvulsant symptom well control . They must stable neurologic status least 1 week prior enrollment study . Must able swallow powder capsule . Have presence either measurable nonmeasurable disease . Have receive treatment within 21 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . Receiving corticosteroid stable decrease dose corticosteroid prior 7 day . Receiving enzymeinducing anticonvulsant . Have serious preexist medical condition . Have current hematologic malignancy acute chronic leukemia . Have know active fungal , bacterial , and/or know viral infection , include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) . Have second primary malignancy , judgment investigator sponsor , may affect interpretation result . Have ≥Grade 2 QT prolongation , , QTc interval &gt; 480 millisecond ( msec ) screen electrocardiography ( ECG ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent medulloblastoma</keyword>
</DOC>